MADRIGAL PHARMACEUTICALS, INC. (MDGL)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$232.2M
Cash & Equivalents
$167.4M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$12,374M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
RESMETIROM
REZDIFFRA |
APPROVED | Cirrhosis, Liver, Drug Safety, Healthy, Hepatic Impairment, Heterozygous Familial Hypercholesterolemia, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH, NASH (Nonalcoholic Steatohepatitis), Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Renal Impairment |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase3 Readout | — |
| 2027-03-01 | Phase3 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07541469 | Rezdiffra Pregnancy and Lactation Registry | OTHER | Recruiting | 10 |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Di... | PHASE3 | Active Not Recruiting | 810 |
| NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | PHASE3 | Active Not Recruiting | 1,759 |
| NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhos... | PHASE3 | Active Not Recruiting | 845 |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | PHASE2 | Recruiting | 120 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.